Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap - 25/03/22
, Jannik Helweg-Larsen b, Morten Steensen c, Maiken Cavling Arendrup d, e, f, Marie Helleberg a, b
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Mucormycosis has recently been recognized as a severe complication of COVID-19 with high fatality rates. We report a fatal case of COVID-19 associated mucormycosis (CAM) in a non-diabetic immunocompromised patient, who was first misdiagnosed and treated for COVID-19 associated aspergillosis (CAPA). The risk factors and initial clinical presentation of CAPA and CAM are similar, but CAM has a more aggressive course and CAPA and CAM are treated differently. Dedicated diagnostic workup is essential to ensure early treatment of CAM with surgical debridement and targeted antifungal therapy.
El texto completo de este artículo está disponible en PDF.Keywords : COVID-19, Mucormycosis, Immunosuppression, SARS-COV-2, Rhizopus microsporum, Invasive fungal infection
Esquema
Vol 32 - N° 1
Artículo 101228- mars 2022 Regresar al número
Artículo precedente
- Successful treatment of Talaromyces marneffei infection in a kidney transplant recipient with voriconazole followed by itraconazole for the first time
- Yunfei Li, Mimi Tang, Shusen Sun, Qin Hu, Sheng Deng
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.